Intraperitoneal GM-CSF and Antimicrobial Composition for Peritonitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infectious peritonitis, particularly those involving systemic administration of GM-CSF, often fail to effectively restore peritoneal macrophage function and achieve high local antimicrobial concentrations, leading to suboptimal outcomes in patients with peritonitis.
Innovation Solution
The use of intraperitoneal administration of GM-CSF combined with appropriate antimicrobial agents, such as fosfomycin and metronidazole, to directly target the peritoneal cavity, enhancing local antimicrobial defense and recruiting primed macrophages without systemic inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of GM-CSF is used, then peritoneal macrophage function is restored, but high local antimicrobial concentrations cannot be achieved
Solution Approach 1:
The treatment is segmented into two separate compositions: one containing GM-CSF for intraperitoneal administration to restore macrophage function, and another containing antimicrobial agents for intraperitoneal instillation to achieve high local concentrations. This segmentation allows each component to fulfill its specific function without compromising the other.
Solution Approach 2:
The peritoneal cavity serves as an intermediary space where GM-CSF acts on macrophages to enhance their antimicrobial activity, while simultaneously allowing direct instillation of high concentrations of antimicrobial agents. The macrophages act as biological intermediaries that amplify the therapeutic effect of both components.
2Reliability
If systemic administration of GM-CSF is used, then peritoneal macrophage function is restored, but systemic inflammation occurs
Solution Approach 1:
The GM-CSF is administered locally into the peritoneal cavity rather than systemically, creating a localized high concentration at the site of infection. This local administration restores macrophage function precisely where needed while minimizing systemic exposure and avoiding the harmful effect of systemic inflammation.
Solution Approach 2:
The treatment is segmented into separate intraperitoneal administrations of GM-CSF and antimicrobial agents, allowing localized action within the peritoneal cavity. This segmentation confines the therapeutic effects and potential side effects to the local site, preventing systemic inflammation while maintaining effective macrophage function restoration.
3Reliability
If high local antimicrobial concentrations are achieved, then infection is treated effectively, but systemic side effects increase
Solution Approach 1:
Antimicrobial agents are administered by direct intraperitoneal instillation, creating extremely high local concentrations at the infection site that are many times higher than those achievable by systemic administration. This local quality approach ensures effective infection treatment while limiting systemic exposure and reducing systemic side effects.
Solution Approach 2:
The use of intraperitoneal instillation utilizes fluid dynamics to distribute the antimicrobial solution throughout the peritoneal cavity, ensuring widespread local coverage of the infection site. The hydraulic approach allows high concentrations to be maintained locally without requiring systemic circulation, thereby minimizing systemic side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves peritoneal antimicrobial defense, achieving high local concentrations of antimicrobial agents and enhancing patient outcomes by directly addressing the infection site, reducing systemic side effects and improving survival rates.
Implementation Method 1
GM-CSF is a cytokine of the colony-stimulating factor family which is secreted by macrophages, T cells, mast cells, natural killer (NK) cells, endothelial cells and fibroblasts. It is also secreted by the peritoneal mesothelial cells, the main fixed cell component of the peritoneal membrane.
Implementation Method 2
GM-CSF functions as a white blood cell growth factor, stimulating stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells.
Implementation Method 3
The prime candidate antibiotic that is active against all the causative aerobic bacteria found in infectious peritonitis is fosfomycin. Intraperitoneal administration of the antibiotic results in high local concentrations that are many times higher than the minimum inhibitory concentrations for even the organisms that are regarded as relatively resistant to fosfomycin.
Data Source
AI summary
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.